Can-Fite Advances Pancreatic Cancer Trial, Awaits Q3 Data
Event summary
- Can-Fite BioPharma has completed patient enrollment for a Phase 2a clinical trial of Namodenoson in patients with advanced pancreatic adenocarcinoma.
- The trial is evaluating safety, clinical activity, and pharmacokinetics of Namodenoson, with a primary safety endpoint already demonstrated.
- Top-line efficacy data is expected in Q3 2026.
- Namodenoson is an A3 adenosine receptor (A3AR) agonist and has received Orphan Drug Designation for pancreatic cancer treatment.
- The trial is led by Prof. Salomon Stemmer at the Davidoff Center, Rabin Medical Center.
The big picture
Pancreatic cancer represents a significant unmet medical need with limited treatment options. Can-Fite's Phase 2a trial represents a potential advancement in targeted therapies for this aggressive disease, but the small sample size and open-label design limit the conclusions that can be drawn. The Orphan Drug Designation provides incentives for development, but successful commercialization will depend on demonstrating meaningful efficacy and a favorable safety profile.
What we're watching
- Efficacy Readout
- The Q3 2026 efficacy data release will be critical in determining the potential of Namodenoson as a treatment option for pancreatic cancer, a disease with high unmet need.
- Regulatory Pathway
- How the FDA will interpret the Phase 2a data, particularly given the Orphan Drug Designation, will influence the potential for accelerated approval or further development.
- Competitive Landscape
- The success of Namodenoson will be weighed against the progress of other novel therapies targeting pancreatic cancer, which remains a challenging therapeutic area.
Related topics